| Medical and Health Sciences | Lifetime | 251 | CA 10 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 571 | CA 19 | 99.88 |
| Nephrology | Lifetime | 9 | CA 1 | 99.95 |
| Emergency Medical Services | Lifetime | 44 | CA 3 | 99.43 |
| Public, Environmental and Occupational Health | Lifetime | 643 | CA 40 | 99.10 |
| Surgery | Lifetime | 932 | CA 50 | 99.11 |
| Cardiology and Cardiovascular Medicine | Lifetime | 754 | CA 48 | 98.49 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 883 | CA 31 | 96.65 |
| Transplantation | Lifetime | 129 | CA 4 | 96.00 |
| Hematology | Lifetime | 971 | CA 49 | 89.32 |
| Nephrology | 2021-2025 | 28 | CA 2 | 99.34 |
| Public, Environmental and Occupational Health | 2021-2025 | 770 | CA 45 | 92.42 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 764 | CA 48 | 85.56 |
| Chronic Kidney Disease and Diabetes | Lifetime | 4 | CA 1 | 99.94 |
| Dialysis and Renal Disease Management | Lifetime | 5 | CA 1 | 99.95 |
| Central Venous Catheters and Hemodialysis | Lifetime | 25 | CA 2 | 99.65 |
| Chronic Disease Management Strategies | Lifetime | 36 | CA 4 | 99.40 |
| Renal and Vascular Pathologies | Lifetime | 41 | CA 4 | 99.53 |
| Organ Donation and Transplantation | Lifetime | 33 | CA 3 | 99.54 |
| Renal Transplantation Outcomes and Treatments | Lifetime | 76 | CA 6 | 99.47 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 161 | CA 15 | 99.46 |
| Acute Kidney Injury Research | Lifetime | 44 | CA 7 | 99.31 |
| Blood Pressure and Hypertension Studies | Lifetime | 134 | CA 7 | 99.49 |
| Erythropoietin and Anemia Treatment | Lifetime | 36 | CA 2 | 99.15 |
| Vascular Procedures and Complications | Lifetime | 123 | CA 5 | 98.84 |
| Lipoproteins and Cardiovascular Health | Lifetime | 191 | CA 13 | 99.09 |
| Renal Diseases and Glomerulopathies | Lifetime | 226 | CA 12 | 98.72 |
| Parathyroid Disorders and Treatments | Lifetime | 194 | CA 9 | 98.62 |
| Diabetes Treatment and Management | Lifetime | 351 | CA 16 | 98.67 |
| Healthcare cost, quality, practices | Lifetime | 156 | CA 14 | 97.62 |
| Healthcare Systems and Reforms | Lifetime | 162 | CA 6 | 97.66 |
| Vascular anomalies and interventions | Lifetime | 166 | CA 10 | 97.63 |
| Pharmaceutical Economics and Policy | Lifetime | 218 | CA 14 | 96.97 |
| Potassium and Related Disorders | Lifetime | 162 | CA 13 | 96.82 |
| Clinical practice guidelines implementation | Lifetime | 401 | CA 56 | 95.83 |
| Pregnancy and Medication Impact | Lifetime | 371 | CA 38 | 96.08 |
| Global Public Health Policies and Epidemiology | Lifetime | 494 | CA 25 | 94.95 |
| Neurological Complications and Syndromes | Lifetime | 323 | CA 13 | 94.89 |
| Primary Care and Health Outcomes | Lifetime | 991 | CA 89 | 95.48 |
| Magnesium in Health and Disease | Lifetime | 191 | CA 7 | 94.73 |
| Electrolyte and hormonal disorders | Lifetime | 917 | CA 39 | 93.59 |
| Neurological and metabolic disorders | Lifetime | 503 | CA 24 | 91.90 |
| Muscle and Compartmental Disorders | Lifetime | 809 | CA 43 | 87.57 |
| Health Promotion and Cardiovascular Prevention | Lifetime | 794 | CA 42 | 86.98 |
| Dialysis and Renal Disease Management | 2021-2025 | 23 | CA 3 | 99.23 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 32 | CA 4 | 99.04 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 255 | CA 24 | 97.37 |
| Renal and Vascular Pathologies | 2021-2025 | 69 | CA 3 | 96.40 |
| Organ Donation and Transplantation | 2021-2025 | 165 | CA 15 | 93.41 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 416 | CA 17 | 92.68 |
| Chronic Disease Management Strategies | 2021-2025 | 463 | CA 32 | 89.79 |
| Renal Transplantation Outcomes and Treatments | 2021-2025 | 612 | CA 40 | 90.51 |
| Frailty in Older Adults | 2021-2025 | 727 | CA 38 | 89.97 |
| Acute Kidney Injury Research | 2021-2025 | 443 | CA 18 | 85.32 |
| Healthcare cost, quality, practices | 2021-2025 | 342 | CA 30 | 84.75 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 196 | CA 6 | 82.96 |
| Clinical practice guidelines implementation | 2021-2025 | 621 | CA 80 | 72.86 |
| Neurological and metabolic disorders | 2021-2025 | 537 | CA 19 | 50.20 |
| Pharmaceutical industry and healthcare | 2021-2025 | 556 | CA 43 | 36.26 |
| Travel-related health issues | 2021-2025 | 931 | CA 27 | 27.29 |
| Magnesium in Health and Disease | 2021-2025 | 888 | CA 31 | 25.48 |